Gold prices bounce off 3-week lows; demand likely longer term
Daniel J. Lippis, Corporate Vice President of JAPAC at Edwards Lifesciences Corp (NYSE:EW), a $40 billion medical technology company with strong financial health according to InvestingPro analysis, recently executed a series of stock transactions as detailed in a recent SEC filing. On March 10, Lippis sold 400 shares of common stock at a price of $69.48 each, totaling $27,792. The transactions were part of a pre-established Rule 10b5-1 trading plan, adopted on December 11, 2023. The sale occurred as the company maintains a robust balance sheet with more cash than debt and an impressive current ratio of 4.18x.
In addition to the sale, Lippis exercised options to acquire 400 shares at a price of $45.2767 per share, amounting to a total value of $18,110. Following these transactions, Lippis holds 22,588.0651 shares in the company.
These transactions reflect changes in Lippis’s beneficial ownership of the company’s stock, executed under the framework of a planned trading strategy.
In other recent news, Edwards Lifesciences reported strong financial results for the fourth quarter of 2024, surpassing analysts’ expectations with a revenue of $1.39 billion and an adjusted earnings per share (EPS) of $0.59. This marked a 9% year-over-year revenue growth, driven by robust performance in the Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The TAVR segment alone generated $1.04 billion in revenue, reflecting a 5.3% increase, while the TMTT division saw an impressive 85% growth in sales. Following these results, Canaccord Genuity increased its price target for Edwards Lifesciences to $71, maintaining a Hold rating, whereas Stifel reiterated a Buy rating with a $90 price target, expressing confidence in the company’s growth trajectory.
The company’s management has reiterated its financial guidance for 2025, projecting total company sales between $5.6 billion and $6.0 billion. They anticipate TAVR sales between $4.1 billion and $4.4 billion and TMTT sales between $500 million and $530 million. Edwards Lifesciences plans to maintain a strong focus on expanding its global presence and investing in research and development. Despite positive results, Canaccord remains cautious, citing the need for further developments in the TMTT segment before altering their position on the stock. Meanwhile, the company’s strategic focus on structural heart disease and recent acquisitions were highlighted as key factors supporting its growth outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.